Greg M Delgoffe, PhD
Campus: 5117 Centre Ave
Office: 2.26b HCC
Lab: 2.19 HCC
Pittsburgh, PA 15232
- St. Jude Children's Research Hospital, Postdoc
- Johns Hopkins University, PhD
- Western Michigan University, BS
- Associate Professor, Department of Immunology
- Member, Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center
- Chair, Program in Microbiology and Immunology Admissions Committee
The Delgoffe Lab studies the metabolic contributions to T cell fate and function. The activation, expansion, and differentiation of T cells requires the interpretation of many complex signals including those from the antigen receptor, costimulatory and coinhibitory molecules, and cytokines. It has now become clear that metabolism represents another key mechanism by which T cells can be regulated. In addition, nutrient sensing and metabolic reprogramming pathways are intrinsically tied to signaling involved in T cell biology. Given that nutrients are limiting in the microenvironment of cancer, our studies have immediate translation as modalities to improve cancer immunotherapy.
Metabolic barriers to effective cancer immunotherapy
Cancer cells, by nature of their unrestrained proliferation, are metabolically deregulated. This results in both a local depletion of nutrients and oxygen but also a build-up of toxic byproducts. This creates an inhospitable environment for infiltrating immune cells, suggesting that tumor cells evade immunity in part by starving tumor-reactive cells. Our lab studies how hypoxia, acidosis, and local nutrient depletion represent barriers to immunotherapies like adoptive cell therapy, costimulatory therapy, oncolytic viruses, and checkpoint blockade. Further, our work has identified pharmacologic modalities by which tumor cell metabolism can be remodeled, leading to improved immunotherapy responses. Some of these modalities are being translated into clinical trials here in Pittsburgh and beyond.
Metabolic underpinnings to T cell exhaustion
T cell exhaustion is a defined functional state in which terminally differentiated T cells become hyporesponsive to their antigen. Persistent antigen in chronic viral infection and in cancer represent key drivers of this phenotype, but it is still unclear how T cell exhaustion is induced and why, precisely, exhausted T cells are dysfunctional. The laboratory has found that exhausted T cells lost functional mitochondria and that this metabolic insufficiency underlies both their differentiation and dysfunction. We utilize cutting edge technology to profile the contributions of metabolic pathways to the avoidance of the exhausted T cell phenotype and explore novel ways to reverse T cell exhaustion to improve therapies.
Regulatory T cell metabolism and its implication in cancer and autoimmunity
Regulatory T cells are vital components of a healthy immune system but become dysfunctional in autoimmunity and hyperactive in cancer. Our laboratory studies how tissue-resident and tumor-resident regulatory T cells meet their metabolic demands, and have found that these cells have unique metabolic profiles that underlie their functional identity. Projects in the lab seek to understand the contribution of these novel metabolic pathways to regulatory T cell function and explore how to exploit these potential metabolic vulnerabilities to combat cancer and autoimmunity.
Oncolytic virus immunotherapy and modalities for therapeutic enhancement
While checkpoint blockade immunotherapy can reinvigorate resident, dormant antitumor immunity, many microenvironments are either immune excluded (in which T cells cannot penetrate the tumor bed) or immune desert (in which T cells are present whatsoever), and represent poor response to checkpoint blockade. Oncolytic viruses are engineered agents which replicate specifically in tumor cells and lead to cancer cell lysis. Further, these viruses stimulate potent, new tumor immunity dominated by T cells. Our lab studies the mechanisms by which oncolytic viruses function to stimulate new immunity and how the virus itself can be employed to deliver metabolic modulatory therapy.
Energetic contributions to T cell activation and motility
Early in our lab’s history we found that T cells make drastic changes to their metabolic program almost immediately upon TCR ligation (within minutes). We hypothesize this is due to immediate metabolic requirements necessary for early T cell function. Our lab seeks to understand the molecular players present in the metabolic program of T cells, how the TCR communicates with the metabolic machinery, and how these very early metabolic programs promote T cell effector function and cellular dynamics.
Therapeutic improvement of chimeric antigen receptor T cell function via metabolic reprogramming
Chimeric antigen receptor T cells are a form of adoptive cell therapy in which healthy blood T cells are redirected to tumor antigens by exogenously expressing a chimeric receptor which recognizes a tumor antigen on the surface but delivers T cell costimulation and activation intracellularly. These redirected T cells are then infused back into the patient where they seek out and kill tumor cells. In hematologic malignancies CAR-T cells have had extremely dramatically clinical results, but these cellular therapies have shown almost no efficacy in solid tumors. We hypothesize the same types of metabolic suppression we observe in endogenous T cells occur in these cells, suggesting that metabolic reprogramming may also enable CAR-T therapy in solid tumors.
Rivadeneira DB, DePeaux K, Kulkarni A, Tabib T, Menk AV, Sampath P, Lafyatis R, Ferris RL, Sarkar SN, Thorne SH, and Delgoffe GM. “Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance.” Immunity. 2019 Aug 27.
Najjar YG, Menk AV, Sander C, Rao U, Karunam urthy A, Bhatia R, Zhai S, Kirkwood JM, Delgoffe GM. “Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma.” JCI Insight. 2019 Feb 5. 2019. Mar 7; 4(5).
Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, Watkins SC, Delgoffe GM. 41BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J. Exp Med. 2018 Mar 2.
Menk AV, Scharping NE, Moreci RS, Zeng X, Guy C, Salvatore S, Bae H, Xie J, Young HA, Wendell SG, and Delgoffe GM. Early TCR signaling induces rapid aerobic glycolysis enabling distinct acute T cell effector functions. Cell Rep. 2018 Feb 6;22(6):1509-1521.
Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM. “The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction.” Immunity. 2016 Aug 16;45(2):374-88.
Scharping NE*, Menk AV*, Whetstone RD, Zeng X, Delgoffe GM. "Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia." Cancer Immunol Res. 2016 Dec 9.
Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, Stelekati E, McLane LM, Paley MA, Delgoffe GM, Wherry EJ. “Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion.” Immunity. 2016 Aug 16;45(2):358-73.
Pollizzi KN, Sun IH, Patel CH, Lo YC, Oh MH, Waickman AT, Tam AJ, Blosser RL, Wen J, Delgoffe GM, Powell JD. “Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation.” Nat Immunol. 2016 Jun;17(6):704-11.
Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DA. “Interleukin-35 Limits Anti-Tumor Immunity.” Immunity. 2016 Feb 16;44(2):316-29.Delgoffe GM, Powell JD. “Feeding an army: The metabolism of T cells in activation, anergy, and exhaustion.” Mol Immunol. 2015 Dec;68(2 Pt C):492-
Pollizzi KN, Patel CH, Sun IH, Oh MH, Waickman AT, Wen J, Delgoffe GM, and Powell JD. "mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation." J Clin Invest. 2015 125(5):2090-108.
Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, Bettini ML, Vogel P, Finkelstein D, Bonnevier J, Workman CJ, Vignali DA. "Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis.” Nature. 501 (7466) , pp. 252-256. 2013 Sep 12. doi:10.1038/nature12428
Collison LW*, Delgoffe GM*, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ, Vignali DA. “The composition and signaling of the IL-35 receptor are unconventional.” Nat Immunol. 2012 Feb 5. doi: 10.1038/ni.2227.
Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF, and Powell JD. “The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.” Nat Immunol. 2011 Feb 27.
Zheng Y*, Delgoffe GM*, Meyer CF*, Chan W, Powell JD. "Anergic T cells are metabolically anergic." J Immunol. 2009 Oct 19.
Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthew KL, Xiao B, Worley PF, Kozma SC, Powell JD. “The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.” Immunity. 2009 Jun 19; 30(6):832-44.
- tumor immunology
- regulatory T cell biology
The Delgoffe Lab is located at the UPMC Hillman Cancer Center in Shadyside, although you will frequently find Dr. Delgoffe running all about town collaborating with folks in Oakland, Children's, and Bridgeside Point.
Dr. Delgoffe also runs the Grad Student/Postdoc Research-In-Progress Seminar Series, serves as Chair on the Program for Microbiology and Immunology Admissions Committee, and serves on the Advisory Board for the UPMC Immune Transplant and Therapy Center (ITTC).